Novel Anticancer Drug Protocols

Overview of Novel Anticancer Drug Targets.- Kinase Inhibitor Discovery Protocols.- Biomarker Assays for Phosphorylated MAP Kinase.- Assays for Cyclin-Dependent Kinase Inhibitors.- Identifying Inhibitors of ATM and ATR Kinase Activities.- Angiogenesis and Metastasis Protocols.- The Rat Aortic Ring Assay for In Vitro Study of Angiogenesis.- Real Time In Vivo Quantitation of Tumor Angiogenesis.- Use of Tumor-Activated Hepatic Stellate Cell as a Target for the Preclinical Testing of Anti-Angiogenic Drugs Against Hepatic Tumor Development.- Cell Motility, Adhesion, Homing, and Migration Assays in the Studies of Tyrosine Kinases.- Inflammatory Response of Tumor-Activated Hepatic Sinusoidal Endothelium as a Target for the Screening of Metastasis Chemopreventive Drugs.- Binding Assay for Selectins.- Determination of Peak Serum Levels and Immune Response to the Humanized Anti-Ganglioside Antibody-Interleukin-2 Immunocytokine.- Immunohistochemical Assays in the Clinical Setting.- Immunohistochemical Determination of EGFR-Tyrosine Kinase Inhibition in Clinical Samples.- Immunohistochemical Assays of Farnesyltransferase Inhibition in Patient Samples.- Protein Chaperoning/Degradation Protocols.- Assays for HSP90 and Inhibitors.- Assays for Proteasome Inhibition.- Protein-Protein and Protein-DNA Interactions.- The Mammalian Two-Hybrid Assay for Detection of Coactivator-Nuclear Receptor Interactions.- Preparation of DNA-Protein Complexes Suitable for Spectroscopic Analysis.- Antisense.- Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression.- Genomics.- Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms.- Gene Expression Microarrays.- Methods for Isolation and Genetic Analysis of Circulating Tumor DNA in Patient Plasma.- Cell Lifespan/Longevity.- The Use of Early Sea Urchin Embryos in Anticancer Drug Testing.- In Vivo Imaging.- PET Screening of Anticancer Drugs.- Miscellaneous Protocols.- Assays for In Vitro and In Vivo Synergy.- Flow Cytometric